Italia markets closed

XOMA Corporation (0M26.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
13,96-1,57 (-10,13%)
Alla chiusura: 03:39PM BST
Schermo intero
Chiusura precedente15,53
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno0,00 - 0,00
Intervallo di 52 settimane
Media Volume65
Beta (5 anni mensile)0,86
Rapporto PE (ttm)0,14
EPS (ttm)1,00
Prossima data utili01 nov 2023 - 06 nov 2023
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    XOMA Declares Quarterly Preferred Stock Dividends

    EMERYVILLE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series

  • GlobeNewswire

    XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference

    EMERYVILLE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, will present a company update at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 9:30 AM ET. The conference is being held in New York, NY. The presentation can be accessed at or by visiting the investor relations section of the company’s website at

  • GlobeNewswire

    XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

    Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset Two portfolio assets are now generating cash flows from commercial sales Company expects at least one partner to file a New Drug Application in third quarter of 2023 EMERYVILLE, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its second quarter 2023 financial results and highlighted recent